- Home
- MGN vs HOWL Comparison
MGN vs HOWL Comparison
Compare MGN & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | HOWL |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 30.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGN | HOWL |
|---|---|---|
| Price | $2.67 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 488.0K | 372.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.53 |
| 52 Week High | $3.99 | $2.23 |
Technical Indicators
Market Signals| Indicator | MGN | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 59.60 |
| Support Level | $1.42 | $0.56 |
| Resistance Level | N/A | $0.74 |
| Average True Range (ATR) | 0.44 | 0.05 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 77.52 | 88.37 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.